Madrigal Pharmaceuticals, Inc.
MDGLNASDAQHealthcare● Active
$486.98
$-5.85(-1.19%)
Market Cap$11.2B
P/E Ratio—
52W High$615
52W Low$271.96
Madrigal Pharmaceuticals, Inc. (MDGL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MDGL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$3.25
Est. -$3.61 · +10.0%
Revenue
$0.31B
Est. $0.30B · +3.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
MDGL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $7.60B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$7.60B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$2.23 | — | — | — | $0.35B | — |
| ▲ Q2 FY2026 | May 6, 2026 | -$3.61 | -$3.25 | +10.0% | $0.31B | $0.30B | +3.4% |
| ▼ Q1 FY2026 | Feb 19, 2026 | $0.04 | -$2.57 | -6525.0% | $0.32B | $0.31B | +2.8% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$2.04 | -$5.08 | -149.4% | $0.29B | $0.24B | +17.3% |
| ▲ Q3 FY2025 | Aug 5, 2025 | -$3.48 | -$1.90 | +45.4% | $0.21B | $0.24B | -12.6% |
| ▲ Q2 FY2025 | May 1, 2025 | -$3.62 | -$3.32 | +8.3% | $0.14B | $0.16B | -13.6% |
| ▲ Q1 FY2025 | Feb 26, 2025 | -$4.32 | -$2.71 | +37.3% | $0.10B | $0.10B | +5.6% |
| ▲ Q4 FY2024 | Oct 31, 2024 | -$6.94 | -$4.92 | +29.1% | $0.06B | $0.09B | -32.8% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$2.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
-$3.25
EPS Est.
-$3.61
EPS Surpr.
+10.0%
Revenue
$0.31B
Q1 FY2026
Feb 19, 2026Miss
EPS Actual
-$2.57
EPS Est.
$0.04
EPS Surpr.
-6525.0%
Revenue
$0.32B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$5.08
EPS Est.
-$2.04
EPS Surpr.
-149.4%
Revenue
$0.29B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
-$1.90
EPS Est.
-$3.48
EPS Surpr.
+45.4%
Revenue
$0.21B
Q2 FY2025
May 1, 2025Beat
EPS Actual
-$3.32
EPS Est.
-$3.62
EPS Surpr.
+8.3%
Revenue
$0.14B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
-$2.71
EPS Est.
-$4.32
EPS Surpr.
+37.3%
Revenue
$0.10B
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
-$4.92
EPS Est.
-$6.94
EPS Surpr.
+29.1%
Revenue
$0.06B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $4.64 | $4.91 | $5.20 | 2 |
| Q3 FY2027 | $2.96 | $3.13 | $3.31 | 1 |
| Q2 FY2027 | $1.83 | $1.94 | $2.05 | 1 |
| Q1 FY2027 | $0.53 | $0.56 | $0.59 | 2 |
| Q4 FY2026 | $0.07 | $0.08 | $0.08 | 2 |
| Q3 FY2026 | $-1.08 | $-0.84 | $-0.64 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.6B | $0.6B | $0.7B | 4 |
| Q3 FY2027 | $0.5B | $0.6B | $0.6B | 5 |
| Q2 FY2027 | $0.5B | $0.5B | $0.5B | 4 |
| Q1 FY2027 | $0.4B | $0.5B | $0.5B | 4 |
| Q4 FY2026 | $0.4B | $0.4B | $0.5B | 8 |
| Q3 FY2026 | $0.4B | $0.4B | $0.4B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +10.0% | $502.47 | $539.73 | +7.42% |
| ▼ Q1 FY2026 | Feb 19, 2026 | -6525.0% | $491.49 | $436.87 | -11.11% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -149.4% | $412.35 | $444.64 | +7.83% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +45.4% | $312.11 | $338.91 | +8.59% |
| ▲ Q2 FY2025 | May 1, 2025 | +8.3% | $333.91 | $327.70 | -1.86% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +37.3% | $309.49 | $355.88 | +14.99% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +29.1% | $215.93 | $259.34 | +20.10% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +6.0% | $266.56 | $234.08 | -12.18% |
Q2 FY2026+7.42%
Report Date
May 6, 2026
EPS Beat/Miss
+10.0%
Price Before
$502.47
Price After
$539.73
Q1 FY2026-11.11%
Report Date
Feb 19, 2026
EPS Beat/Miss
-6525.0%
Price Before
$491.49
Price After
$436.87
Q4 FY2025+7.83%
Report Date
Nov 4, 2025
EPS Beat/Miss
-149.4%
Price Before
$412.35
Price After
$444.64
Q3 FY2025+8.59%
Report Date
Aug 5, 2025
EPS Beat/Miss
+45.4%
Price Before
$312.11
Price After
$338.91
Q2 FY2025-1.86%
Report Date
May 1, 2025
EPS Beat/Miss
+8.3%
Price Before
$333.91
Price After
$327.70
Q1 FY2025+14.99%
Report Date
Feb 26, 2025
EPS Beat/Miss
+37.3%
Price Before
$309.49
Price After
$355.88
Q4 FY2024+20.10%
Report Date
Oct 31, 2024
EPS Beat/Miss
+29.1%
Price Before
$215.93
Price After
$259.34
Q3 FY2024-12.18%
Report Date
Aug 7, 2024
EPS Beat/Miss
+6.0%
Price Before
$266.56
Price After
$234.08
Avg Beat Reaction+6.18%
Avg Miss Reaction-1.64%
Beat Rate6 / 8 quarters
Largest Move+20.10% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MDGL ends December
Madrigal Pharmaceuticals, Inc. (MDGL) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-3.25 — beating the analyst consensus of $-3.61 by +10.0%. The next MDGL earnings date is expected around September 1, 2026.
Each quarter, investors track MDGL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MDGL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MDGL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MDGL earnings · 5 questionsMadrigal Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. MDGL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MDGL historically reports after market close (AMC).
MDGL earnings datewhen is MDGL earningsMDGL next earnings datewhen does MDGL report earningsMDGL earnings calendar
▸ Source: FMP · Madrigal Pharmaceuticals, Inc. SEC filings · US GAAP · Madrigal Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026